NCT01734850: A reported trial by Calimmune, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01734850 |
|---|---|
| Title | An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 30, 2013 |
| Completion date | Sept. 30, 2017 |
| Required reporting date | Sept. 30, 2020, midnight |
| Actual reporting date | June 25, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |